- Home
- HTD vs URGN Comparison
HTD vs URGN Comparison
Compare HTD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- URGN
- Stock Information
- Founded
- HTD 2004
- URGN 2004
- Country
- HTD United States
- URGN United States
- Employees
- HTD N/A
- URGN N/A
- Industry
- HTD Finance Companies
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- URGN Health Care
- Exchange
- HTD Nasdaq
- URGN Nasdaq
- Market Cap
- HTD 868.1M
- URGN 904.0M
- IPO Year
- HTD N/A
- URGN 2017
- Fundamental
- Price
- HTD $24.36
- URGN $18.10
- Analyst Decision
- HTD
- URGN Strong Buy
- Analyst Count
- HTD 0
- URGN 8
- Target Price
- HTD N/A
- URGN $28.50
- AVG Volume (30 Days)
- HTD 92.3K
- URGN 1.2M
- Earning Date
- HTD 01-01-0001
- URGN 11-05-2025
- Dividend Yield
- HTD 8.59%
- URGN N/A
- EPS Growth
- HTD N/A
- URGN N/A
- EPS
- HTD N/A
- URGN N/A
- Revenue
- HTD N/A
- URGN $94,238,000.00
- Revenue This Year
- HTD N/A
- URGN $39.63
- Revenue Next Year
- HTD N/A
- URGN $111.49
- P/E Ratio
- HTD N/A
- URGN N/A
- Revenue Growth
- HTD N/A
- URGN 10.85
- 52 Week Low
- HTD $16.17
- URGN $3.42
- 52 Week High
- HTD $22.13
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- HTD 46.21
- URGN 44.77
- Support Level
- HTD $24.45
- URGN $17.89
- Resistance Level
- HTD $24.70
- URGN $21.71
- Average True Range (ATR)
- HTD 0.17
- URGN 1.17
- MACD
- HTD -0.04
- URGN -0.30
- Stochastic Oscillator
- HTD 24.47
- URGN 5.50
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.